Literature DB >> 21045011

Warfarin in haemodialysis patients with atrial fibrillation: what benefit?

Felix Yang1, Denise Chou, Paul Schweitzer, Sam Hanon.   

Abstract

Warfarin is commonly used to prevent stroke in patients with atrial fibrillation; however, patients on haemodialysis may not derive the same benefit from warfarin as the general population. There are no randomized controlled studies in dialysis patients which demonstrate the efficacy of warfarin in preventing stroke. In fact, warfarin places the dialysis patient at increased risk for haemorrhagic stroke and possibly ischaemic stroke. Additionally, warfarin increases the risk of major bleeding and has been associated with vascular calcification. Routine use of warfarin in dialysis for stroke prevention should be discouraged, and therapy should only be reserved for dialysis patients at high risk for thrombo-embolic stroke and carefully monitored if implemented.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21045011     DOI: 10.1093/europace/euq387

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  14 in total

1.  Hemorrhage as a life-threatening complication after valve replacement in end-stage renal disease patients.

Authors:  Taro Nakatsu; Nobushige Tamura; Shigeki Yanagi; Shoichi Kyo; Takaaki Koshiji; Ryuzo Sakata
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-04-19

Review 2.  Anticoagulants in atrial fibrillation patients with chronic kidney disease.

Authors:  Robert G Hart; John W Eikelboom; Alistair J Ingram; Charles A Herzog
Journal:  Nat Rev Nephrol       Date:  2012-07-24       Impact factor: 28.314

Review 3.  Atrial Fibrillation and Oral Anticoagulation in Chronic Kidney Disease.

Authors:  Christiane Engelbertz; Holger Reinecke
Journal:  J Atr Fibrillation       Date:  2012-04-14

Review 4.  Management of cardiovascular disease in patients with kidney disease.

Authors:  Mark R Kahn; Michael J Robbins; Michael C Kim; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2013-02-19       Impact factor: 32.419

5.  [Patient selection for the implantation of a left atrial appendage occluder in primary and secondary prevention of cardioembolic stroke in atrial fibrillation].

Authors:  C W Israel; D Ridjab; W N Tschishow; J Buddecke
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2013-03

Review 6.  New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function.

Authors:  Birgitte Klindt Poulsen; Erik Lerkevang Grove; Steen Elkjaer Husted
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

7.  Treatment of atrial fibrillation with warfarin among older adults with end stage renal disease.

Authors:  Jingwen Tan; Sunjae Bae; Jodi B Segal; Junya Zhu; Dorry L Segev; G Caleb Alexander; Mara McAdams-DeMarco
Journal:  J Nephrol       Date:  2017-01-24       Impact factor: 3.902

8.  Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis.

Authors:  Lai-Chu See; Hsin-Fu Lee; Tze-Fan Chao; Pei-Ru Li; Jia-Rou Liu; Lung-Sheng Wu; Shang-Hung Chang; Yung-Hsin Yeh; Chi-Tai Kuo; Yi-Hsin Chan; Gregory Y H Lip
Journal:  Cardiovasc Drugs Ther       Date:  2020-11-19       Impact factor: 3.727

9.  Warfarin use and the risk of stroke, bleeding, and mortality in older adults on dialysis with incident atrial fibrillation.

Authors:  Jingwen Tan; Sunjae Bae; Jodi B Segal; Junya Zhu; G Caleb Alexander; Dorry L Segev; Mara McAdams-DeMarco
Journal:  Nephrology (Carlton)       Date:  2019-02       Impact factor: 2.506

10.  [New oral anticoagulants and chronic kidney disease].

Authors:  R M Bauersachs
Journal:  Internist (Berl)       Date:  2012-12       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.